Speakers

Meet the A³I Symposium faculty.

Brian Modena

Brian Modena

MD, MSc

Founder, Modena Health

Brian Modena is an allergist, asthma researcher, and the founder of Modena Health. His research interests include artificial intelligence and machine learning, gene expression, genetics, the microbiome, and connected devices that support individualized medical treatment. He brings experience in severe asthma research and clinical care across allergic and immunologic conditions.

Read full biography of Brian Modena

Brian Modena, M.D., M.Sc., grew up in a small community in southern West Virginia. Dr. Modena and several members of his immediate family have had severe asthma their entire lives, in addition to the several atopic disorders that frequently accompany childhood-onset asthma: allergic rhinitis, food allergies, eczema, and eosinophilic esophagitis. This experience, combined with a strong desire to solve problems, has motivated and catalyzed research interest in the genetic foundations and molecular causes of asthma and atopic disease. He attended Virginia Tech for his undergraduate studies in Mechanical Engineering and West Virginia University for medical school. His training included Internal Medicine at Scripps Green Clinic and Hospital, specialty training in pediatric and adult allergy, asthma, and immunology at the University of Pittsburgh Medical Center, and a Master's of Science at The Scripps Research Institute's Kellogg School of Science & Technology.

He began his career at Scripps Health in 2014 before moving to National Jewish Health in 2018 as an NIH-funded researcher in the field of severe asthma. He then started his own allergy practice - Modena Health in San Diego in 2022. His research experience and interests include artificial intelligence/machine learning, mRNA gene expression, genetics, the microbiome, and IoT devices to provide individualized and highly focused medical treatment. His clinical experience covers allergies (drug, environmental, and food), asthma, AERD, urticaria, dermatitis, and immune system disorders. He spends his free time exercising (hiking, running, skiing), attending summer concerts, and spending time with his wife, two daughters, and dog.

Welcome & Opening Remarks · Saturday, 8:00 AM
Sally E. Wenzel

Sally E. Wenzel

MD

University of Pittsburgh · Asthma and Environmental Lung Health Institute

Sally Wenzel directs the University of Pittsburgh Asthma and Environmental Lung Health Institute and chairs the Department of Environmental and Occupational Health. Her research has helped define the heterogeneity and molecular phenotypes of asthma, with a focus on severe disease and the influence of environmental exposures.

Read full biography of Sally E. Wenzel

Dr. Sally Wenzel is Director of the University of Pittsburgh Asthma and Environmental Lung Health Institute, and Chair of the Department of Environmental and Occupational Health at the University of Pittsburgh. She has received numerous awards from the American Thoracic Society and the European Respiratory Society and has a passion for improving the understanding of the prevention and treatment of asthma, in particular severe asthma. Her human-based research has been critical to identifying the heterogeneity of asthma, as well as helping to identify novel molecular phenotypes. Her current bench-lab interests include the role of epithelial cells in the modulation of redox balance and mucus production in the airways. She leads efforts to address the effects of the environment on oxidative stress in airway epithelial cells of asthmatic patients. She has authored more than 350 publications. She remains dedicated to improving the health of airway disease patients and training physician scientists.

Opening keynote · Saturday, 8:15 AM
Michael E. Wechsler

Michael E. Wechsler

MD, MMSc

National Jewish Health · Cohen Family Asthma Institute

Michael Wechsler is Professor of Medicine at National Jewish Health, Director of the NJH/Cohen Family Asthma Institute, and Associate Vice President for Innovation and Industry Relations. His clinical and translational research focuses on asthma, COPD, novel therapies, and eosinophilic lung diseases. He has published more than 400 publications and participated as an investigator in over 60 clinical trials.

Read full biography of Michael E. Wechsler

Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver, Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary & critical care medicine, Professor Wechsler’s clinical and translational research focuses on clinical trials in asthma and COPD, novel asthma/COPD therapies, bronchial thermoplasty, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for airways diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, tezepelumab, itepekimab and depemokimab. He has published more than 400 publications relating to asthma, COPD, EGPA and eosinophilic lung diseases, and has been an investigator in over 60 clinical trials. He was a member of the Steering Committee and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN/AsthmaNet), a multicenter asthma clinical trials consortium, as well as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation and the Association of American Physicians, he has participated in many different task forces related to the study of asthma and eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society. He is currently Associate Editor of the journal Chest and has served as Associate Editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.

Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and an MD degree from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.

Sunday keynote · Sunday, 8:15 AM
Matthew Altman

Matthew Altman

MD, MPhil

University of Washington · Benaroya Research Institute

Matthew Altman, MD, MPhil, is an Associate Professor in the Division of Allergy and Infectious Diseases at the University of Washington and an Associate Scientist in the Center for Systems Immunology at Benaroya Research Institute. A physician-scientist trained in allergy and immunology, he specializes in bioinformatics, systems biology, and translational immunology.

Read more of Matthew Altman

His research uses transcriptomics, network biology, machine learning, and integrated multi-omics to understand asthma, respiratory viral infections, and immune-mediated diseases. He helps lead investigations within NIH-funded research programs, including the Human Immunology Project Consortium and the Childhood Asthma in Urban Settings Clinical Research Network. His work connects molecular data with disease mechanisms and treatment response, with a focus on translating research into more personalized care.

Nasal Biomarkers & Predictors · Saturday, 11:15 AM
Max A. Seibold

Max A. Seibold

PhD

National Jewish Health · University of Colorado Anschutz Medical Campus

Max Seibold is a Professor and the Wohlberg and Lambert Chair of Pharmacogenomics at National Jewish Health, where he directs the Computational Biology Program. His research advances precision medicine approaches to prevent asthma and tailor treatment to distinct patient immunoendotypes.

Read about his research of Max A. Seibold

His laboratory studies how genetic background and environmental exposures interact within the airway mucosa to produce disease endotypes characterized by airway inflammation, mucus obstruction, and remodeling. The team combines molecular characterization of airway pathobiology, pathogen profiling, and genetic analyses of minimally invasive nasal epithelial and sputum samples from large, deeply phenotyped early-life and treatment-response cohorts.

The laboratory uses primary human airway epithelial and immune cell models to investigate the mechanisms behind its cohort findings. These models integrate inflammatory and viral exposures with gene-editing technologies and are analyzed through network-based, single-cell, and spatial-omics methods. His group applies parallel methods to skin samples to study the early development of atopic dermatitis and variation in treatment response.

Dr. Seibold leads several NIH-funded cohort studies, including GALA, PRIMERO, HEROS, SUNBEAM, and LEADS. His work has identified genetic, inflammatory, and environmental programs that contribute to disease susceptibility, heterogeneity, and treatment response. He has authored more than 100 peer-reviewed publications.

Asthma Genetics & Prediction · Sunday, 9:00 AM
Andrew A. White

Andrew A. White

MD, FAAAAI, FACAAI

Scripps Clinic · Allergy and Immunology Fellowship

Andrew A. White is the Allergy and Immunology Fellowship program director at Scripps Clinic in San Diego. His interests include chronic rhinosinusitis with nasal polyposis, eosinophilic disorders, drug allergy, and mast cell disorders.

Read full biography of Andrew A. White

Dr. Drew White completed medical school at Hahnemann University in Philadelphia after which he completed his internal medicine training at Naval Medical Center San Diego. He completed his Allergy and Immunology Fellowship at Scripps Clinic in San Diego where he remained as faculty and is now the fellowship program director. His interests include chronic rhinosinusitis with nasal polyposis, eosinophilic disorders, drug allergy and mast cell disorders.

He is the head of the aspirin exacerbated respiratory disease clinic, the principal investigator of the American Institute for Mast Cell Disorders Center of Excellence at Scripps Clinic, and was an author in the 2023 practice parameter update on drug hypersensitivity. He is Past President of the Western Society for Allergy, Asthma and Immunology, on the editorial board of the Annals of Allergy, Asthma and Immunology and is currently serving on the Board of Directors of the AAAAI.

AERD · Saturday, 10:30 AM
Warner W. Carr

Warner W. Carr

MD, FAAAAI, FACAAI, FACP

Chief Strategy Officer, Modena Health

Warner W. Carr is board-certified in allergy and immunology and internal medicine. His approach to care centers on understanding each patient’s most important concern and creating an individualized treatment plan. He has also participated in humanitarian efforts in the United States and abroad.

Read full biography of Warner W. Carr

“I decided to pursue a career in medicine, specifically the specialty of allergy and immunology, because the prospect of being able to make a positive impact on the lives of patients of all ages seemed very rewarding to me. My patients trust my care, and they know that they're important to me – while they’re in the office and after they go home. I ask every new patient, ‘What is the number-one problem you would like me to solve?’ and I then create an individualized treatment plan that can provide them with lasting relief from their condition. One of the best compliments I’ve received is that so many of my patients refer their family members and friends to me.”

“I have a genuine concern for the health and well-being of my patients and for people throughout the world. I've given my time and energy to many organizations and projects. I have traveled to other countries to provide medical care for the underprivileged and have participated in humanitarian efforts at the local, state and national level in the US.”

Dr. Carr is board-certified by the American Board of Allergy & Immunology and the American Board of Internal Medicine. He is a Fellow of the American Academy of Allergy, Asthma & Immunology, the American College of Allergy, Asthma & Immunology, and the American College of Physicians.

Food Allergy · Saturday, 1:00 PM
Paneez Khoury

Paneez Khoury

MD

NIAID · National Institutes of Health

Dr. Paneez Khoury is a Senior Clinician and Investigator at NIAID/NIH and a nationally recognized expert in eosinophilic disorders. She leads clinical and translational research in hypereosinophilic syndromes, EGPA, and eosinophilic gastrointestinal disorders and serves as a principal investigator on clinical trials and natural history studies.

Read full biography of Paneez Khoury

She is also the Program Director of the NIH Allergy and Immunology Fellowship Training Program. In parallel with her clinical and educational work, Dr. Khoury has developed a significant academic focus on, and is a frequent invited speaker on artificial intelligence, with multiple peer-reviewed publications examining AI and augmented intelligence in allergy and immunology, medical education, clinical research, disease endotyping, and the future of physician training and practice.

Eosinophilic Disorders · Saturday, 1:45 PM